Neuroleptic malignant syndrome following levomepromazine discontinuation.
Tanii
Hisashi
H
Saka
Keiichi
K
Inoue
Ken
K
Okada
Motohiro
M
D000328:Adult; D018692:Antimanic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008728:Methotrimeprazine / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D009459:Neuroleptic Malignant Syndrome / Q000188:drug therapy / Q000209:etiology*; D013375:Substance Withdrawal Syndrome / Q000209:etiology*; D014635:Valproic Acid / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use
D018692:Antimanic Agents; D014150:Antipsychotic Agents; D014635:Valproic Acid; D008728:Methotrimeprazine